Clinical Study
Can Serum Tenascin-C Be Used as a Marker of Inflammation in Patients with Dilated Cardiomyopathy?
Table 5
G-peak sl ap lax, G peak sl a2c, G peak sl a4c, and G peak sl avg in group I and group II.
| Tissue | | Range | Mean | ±SD | t-test | P value |
| G peak sl ap lax | Group I | 12 | −7–−20 | | 5.36 | 4.922 | 0.001** | Group II | 12 | −16–−24 | | 2.50 |
| G peak sl a4c | Group I | 12 | −4–−20 | | 5.35 | 2.042 | <0.05* | Group II | 12 | −10–−23 | | 2.574 |
| G peak sl a2c | Group I | 12 | −9–−19 | | 6.53 | 4.227 | 0.001** | Group II | 12 | −15–−25 | | 5.27 |
| Peak sl avg | Group I | 12 | −6–−19 | | 5.62 | 2.585 | <0.05* | Group II | 12 | −18–−24 | | 6.05 |
|
|
**Highly significant, *Significant.
|